NDAORAL-21TABLET
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DEMULEN 1/35-21 (ethinyl estradiol; ethynodiol diacetate) by Pfizer. Approved for pregnancy. First approved in 1981.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMULEN 1/35-21 is an oral contraceptive combination tablet containing ethinyl estradiol and ethynodiol diacetate, approved in 1981. It prevents pregnancy through hormonal suppression of ovulation. The product is a classic combined oral contraceptive indicated for contraception in women of reproductive age.
LOE Approaching
As a legacy contraceptive approaching loss of exclusivity, the brand team is likely consolidating operations and focusing on cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on DEMULEN 1/35-21 offers limited growth trajectory due to the product's mature, declining lifecycle; roles are primarily custodial focused on compliance, brand protection in legacy segments, and managing generic competition. Career advancement typically requires movement to growth-stage products or lateral roles in corporate functions.
Brand Manager
Worked on DEMULEN 1/35-21 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.